The European Commission granted a “Seal of Excellence” to Novosanis’ project proposal UROSCREEN on the use of Colli-Pee in cervical screening programs. Colli-Pee is designed to collect the first-void urine in a non-invasive way. First-void urine can be used for detecting human papillomavirus (HPV) which can cause cervical cancer.
An international panel of independent experts evaluated the UROSCREEN proposal on 4 different criteria: excellence, impact, quality and efficiency of implementation. The panel decided to grant a “Seal of Excellence” and labeled UROSCREEN as an innovative project proposal. This recognition underlines the potential of Colli-Pee in enabling a more efficient screening program on HPV by offering a non-invasive self-sampling device initially to non-attendees of the screening programs. Novosanis submitted the project proposal UROSCREEN to Horizon 2020 in the area of clinical research for the validation of diagnostic medical devices.
Dr. Vanessa Vankerckhoven, CEO of Novosanis, commented: “We are delighted with the recognition by Horizon 2020 and hope this brings more attention to the full potential of Colli-Pee in the screening of patients, especially non-attendees of the screening programs, across Europe.”